Spinal Muscular Atrophy Market Report 2026

Spinal Muscular Atrophy Market Overview

• Spinal Muscular Atrophy market size has reached to $4 billion in 2025 • Expected to grow to $7.34 billion in 2030 at a compound annual growth rate (CAGR) of 12.9% • Growth Driver: Impact Of Rising Prevalence Of Rare Genetic Diseases On the Market • Market Trend: Revolutionizing Early Intervention For Spinal Muscular Atrophy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Spinal Muscular Atrophy Market?

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive loss of motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, resulting in insufficient survival motor neuron (SMN) protein. SMA affects voluntary muscle movements, particularly those involved in walking, swallowing, and breathing. The main types of spinal muscular atrophy are type 1 (severe), type 2 (intermediate), type 3 (mild), and type 4 (adult). Type 1 spinal muscular atrophy (SMA), also known as severe SMA, is the most critical form of the disease, characterized by profound muscle weakness and the inability to sit or move independently, typically leading to death before the age of 2 without treatment. It affects different age groups such as pediatric and adult patients. Treatment options include drug therapy and gene therapy and are used by several end users, including hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Spinal Muscular Atrophy Market Growth Forecast?

The spinal muscular atrophy market size is expected to see rapid growth in the next few years. It will grow to $7.34 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to next-generation gene therapies, global screening adoption, expanded treatment access, improved survival outcomes, pipeline drug development. Major trends in the forecast period include early genetic diagnosis, expansion of disease-modifying therapies, newborn screening programs, personalized treatment protocols, long-term disease management.

Global Spinal Muscular Atrophy Market Segmentation

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult) 2) By Age: Pediatric, Adults 3) By Treatment: Drug Therapy, Gene Therapy 4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy Subsegments: 1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA 2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA 3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA 4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

What Is The Driver Of The Spinal Muscular Atrophy Market?

The rising prevalence of rare genetic diseases is expected to propel the growth of the spinal muscular atrophy market going forward. Rare genetic diseases are disorders caused by mutations in genes that affect a small percentage of the population, often resulting in severe, chronic health problems. The rising prevalence of rare genetic diseases can be attributed to improved diagnostic technologies, increased awareness, and better access to genetic testing, leading to more cases being identified and reported. Spinal muscular atrophy (SMA) is a rare genetic disorder that exemplifies the challenges and opportunities in understanding inherited diseases. It highlights the importance of advancing research into genetic conditions. For instance, in July 2023, according to a report published by the Office for National Statistics, a UK-based government department, genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. Therefore, the rising prevalence of rare genetic diseases will drive the growth of the spinal muscular atrophy industry.

Key Players In The Global Spinal Muscular Atrophy Market

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd, Sarepta Therapeutics, Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences

Global Spinal Muscular Atrophy Market Trends and Insights

Major companies operating in the spinal muscular atrophy market are developing innovative products, such as dry syrup, to improve medication adherence and ease of administration for pediatric and other patient groups with swallowing difficulties. Dry syrup is a powdered medication that is reconstituted with water before use, commonly prescribed for children and patients who have difficulty swallowing tablets or capsules. For instance, in September 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced regulatory approval from Japan's Ministry of Health, Labour and Welfare for an expanded indication of its drug Evrysdi (risdiplam). The approval allows its use in pre-symptomatic spinal muscular atrophy (SMA) and extends dosing to infants under two months old. This milestone is crucial as it enables treatment initiation before symptoms appear, potentially enhancing therapeutic outcomes for affected infants. The decision was supported by data from the RAINBOWFISH study, which assessed Evrysdi's safety and efficacy in infants diagnosed with SMA but not yet symptomatic. Findings showed that treated infants achieved developmental milestones, such as unsupported sitting and improved motor skills, by 12 months, underscoring the drug's potential to transform the disease's progression when administered early.

What Are Latest Mergers And Acquisitions In The Spinal Muscular Atrophy Market?

In January 2024, Voyager Therapeutics, Inc., a US-based biotechnology company, partnered with Novartis AG to advance gene therapies for Huntington’s disease and spinal muscular atrophy. The collaboration leverages Voyager’s proprietary TRACER capsids and cutting-edge technology. Novartis AG is a Switzerland-based company that develops pharmaceuticals, eye care products, and generic drugs.

Regional Outlook

North America was the largest region in the spinal muscular atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Spinal Muscular Atrophy Market?

The spinal muscular atrophy market consists of revenues earned by entities by providing services such as gene delivery services, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The spinal muscular atrophy market also includes sales of therapy products, diagnostic kits, medical devices, and nutritional products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Spinal Muscular Atrophy Market Report 2026?

The spinal muscular atrophy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the spinal muscular atrophy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.